Immunome: An Oncology Powerhouse In The Making [Seeking Alpha]
Atreca, Inc. (BCEL)
Last atreca, inc. earnings: 3/11 04:30 pm
Check Earnings Report
Company Research
Source: Seeking Alpha
IMNM has also acquired AL102 and AL101 from Ayala Pharmaceuticals. AL102 is already in a phase 3 study, with results expected in Q1'25. IMNM is also looking to acquire some antibody-related assets and materials from Atreca, subject to a stockholder vote. IMNM expects its cash to last into at least 2026. I wrote about Immunome ( NASDAQ: IMNM ) twice in 2023, including most recently in September when the company was merging with Morphimmune, and bringing on Clay Siegall as CEO. Siegall's appointment, the pipeline and the cash had me rating the company a strong buy. Since the merger, IMNM has engaged in several business development transactions to further build its pipeline and the technology available to it. This article takes a look at those developments, and why I now rate IMNM a buy rather than a strong buy. ZPC-21 and ZNTL platform acquisition In January, IMNM announced it had licensed ZPC-21, a ROR1 antibody-drug conjugate (ADC), from Zentalis Pharmaceuticals ( ZNTL ), a
Show less
Read more
Impact Snapshot
Event Time:
BCEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCEL alerts
High impacting Atreca, Inc. news events
Weekly update
A roundup of the hottest topics
BCEL
Earnings
- 11/14/23 - Miss
BCEL
Sec Filings
- 4/22/24 - Form DEFM14A
- 4/17/24 - Form 4
- 4/11/24 - Form PREM14A
- BCEL's page on the SEC website